このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

フランスにおける転移性ホルモン感受性前立腺がん患者のアパルタミド投与遵守状況を評価する研究 (OBSAPA)

2026年11月2日 更新者:Janssen Cilag S.A.S.

フランスにおける前向き観察研究:フランスの転移性ホルモン感受性前立腺癌(mHSPC)患者におけるアパルタミドの治療継続率

This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.

調査の概要

研究の種類

観察的

入学 (推定)

540

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Caen、フランス、14076
        • 募集
        • Centre Francois Baclesse

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

サンプリング方法

非確率サンプル

調査対象母集団

Adult male (according to their chromosomal composition at birth) participants with confirmed diagnosis of mHSPC will be enrolled at the time of initiation of treatment with apalutamide.

説明

Inclusion criteria:

  • Male (based on chromosomal composition at birth) and aged greater than or equal to (>=) 18 years.
  • Must have a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
  • Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)
  • Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy [ADT]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion
  • Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection
  • Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide.
  • Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide

Exclusion criteria:

  • Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC
  • Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection
  • Is currently receiving active treatment for prostate cancer as part of an interventional study
  • Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment
  • Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment
  • Beneficiary of State Medical Aid [AME]
  • Does not speak/read French
  • Under guardianship or curatorship
  • Under judicial protection

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Metastatic hormone-sensitive prostate cancer (mHSPC): Routine Clinical Practice Setting

Participants with confirmed diagnosis of mHSPC will be enrolled at the time of initiation of treatment with apalutamide (Month 0) in routine clinical practice and will be followed up until 12 months after end of study visit (Month 12). No intervention will be administered as a part of this study.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants With Adherence to Apalutamide at 12 Months
時間枠:At 12 months

Adherent participants are defined as participants adherent to apalutamide at every visit until 12 months according to the Medication Adherence Report Scale (MARS-5). MARS-5 is a well-known participant-reported adherence measure (PRAM) consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 12 months
Number of Participants Reporting Change in Adherence According to MARS-5 by Apalutamide Formulation
時間枠:At 12 months

Participants with changes in adherence according to the MARS-5, by apalutamide formulation will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 12 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Clinical Risk Factor Among Adherent and Non-adherent Participants: ECOG Status
時間枠:Up to 12 months

Clinical risk factors for treatment the Eastern Cooperative Oncology Group (ECOG) will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Comorbidities
時間枠:Up to 12 months

Clinical risk factors for treatment prostate comorbidities will be reported.

Up to 12 months
Clinical Factors of Adherence at 12 Months: Disease Volume
時間枠:At 12 months

Predictive clinical factors of adherence that is disease volume at 12 months will be reported.

At 12 months
Percentage of Adherent Participants at 3, 6, and 9 Months
時間枠:At 3,6,9 months

Percentage of adherent participants at 3 months, 6 months and 9 months according to the MARS-5 will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication. Participants are asked to evaluate how often they adopt each behavior with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 3,6,9 months
Number of Participants Reporting Change in Adherence According to MARS-5 by Apalutamide Formulation at 3, 6 and 9 Months
時間枠:At 3, 6 and 9 months

Participants with changes in adherence according to the MARS-5, by apalutamide formulation will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 3, 6 and 9 months
Number of Participants with Risk of Non-Adherence as per Social, Psychological, Usage and Rational (SPUR) Factors as per SPUR Adherence Tool
時間枠:Baseline, Months 3, 6, 9 and 12

SPUR is a validated, participant-reported questionnaire that assesses adherence-related behavior across thirteen specific behavioral drivers categorized into four dimensions: Social, Psychological, Usage, and Rational. It consists of 24 items and uses a 5-point Likert scale for each item (ranging from "strongly disagree" to "strongly agree"), with some items reverse-coded to minimize response bias. Scores are calculated for each behavioral driver dimension and score indicating the risk of non-adherence is calculated from them, allowing assessment of global non-adherence risk as well as analysis of the behavioral constituents of that risk by considering the mix of drivers present and their relative importance. Here, higher scores indicate more adherence.

Baseline, Months 3, 6, 9 and 12
Spearman Correlation Coefficients at Baseline and Month 12
時間枠:At Baseline and Month 12

Spearman correlation coefficients between each of the 13 behavioral drivers will be reported.

At Baseline and Month 12
SPUR Global Risk Score at Baseline and Month 12
時間枠:At Baseline and Month 12

SPUR is a validated, participant-reported questionnaire that assesses adherence-related behavior across thirteen specific behavioral drivers categorized into four dimensions: Social, Psychological, Usage, and Rational. It consists of 24 items and uses a 5-point Likert scale for each item (ranging from "strongly disagree" to "strongly agree"), with some items reverse-coded to minimize response bias. Scores are calculated for each behavioral driver dimension and score indicating the risk of non-adherence is calculated from them, allowing assessment of global non-adherence risk as well as analysis of the behavioral constituents of that risk by considering the mix of drivers present and their relative importance. Here, higher scores indicate more adherence.

At Baseline and Month 12
Functional Assessment of Cancer Therapy- Prostate (FACT-P) Score
時間枠:At Baseline, Months 3, 6, 9, 12

The FACT-P questionnaire is used to assess quality of life (QoL) in men undergoing therapy for prostate cancer. It is composed of 39 items using a 5-point Likert-like scale. Each item is rated on a 0 to 4, and then combined to produce subscale scores, as well as a global QoL score. Higher scores represent better QoL.

At Baseline, Months 3, 6, 9, 12
Change from Baseline in FACT-P Score at 3, 6 and 9 Months
時間枠:Baseline, Months 3, 6, 9, 12

The FACT-P questionnaire is used to assess quality of life in men undergoing therapy for prostate cancer. It is composed of 39 items using a 5-point Likert-like scale. Each item is rated on a 0 to 4 , and then combined to produce subscale scores, as well as a global QoL score. Higher scores represent better QoL.

Baseline, Months 3, 6, 9, 12
Demographics Characteristics of Participants: Age
時間枠:Baseline

The demographic characteristics of participants that is, age will be reported.

Baseline
Demographics Characteristics of Participants: Socio-Professional Category
時間枠:Baseline

The demographic characteristics of participants that is, socio-professional category (the participant's last occupation held prior to retirement: Managerial [higher managerial or lower managerial], Non-managerial [intermediate or small employers or lower supervisory or semi-routine or routine], Never worked or long-term unemployed will be reported.

Baseline
Demographics Characteristics of Participants: G8 Geriatric Screening Score
時間枠:Baseline

The demographic characteristics of participants that is, G8 geriatric screening score will be reported. The G8 consists of eight items: participant age (greater than [>]85, 80-85, less than [<]80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with higher scores indicating a lower risk of impairments.

Baseline
Prostate-Specific Antigen (PSA) Level at Androgen-Deprivation Therapy (ADT) Initiation
時間枠:Up to 12 months

PSA levels at ADT initiation will be reported.

Up to 12 months
PSA Level at Baseline
時間枠:At Baseline

PSA levels at baseline will be reported.

At Baseline
Change from Baseline in PSA Levels
時間枠:Baseline up to 12 months

Change from baseline in PSA levels will be reported.

Baseline up to 12 months
Serum Testosterone at Baseline
時間枠:At baseline

Serum testosterone levels will be reported.

At baseline
Time from Initial Diagnosis of Prostate Cancer to Metastatic Stage
時間枠:Baseline up to 12 months

Time from initial diagnosis of prostate cancer to metastatic stage for metachronous participants will be reported.

Baseline up to 12 months
Type of Imaging Methods Used for Cancer Diagnostics
時間枠:Baseline

Number of participants with different type of imaging methods used for cancer diagnostic (for example, magnetic resonance imaging [MRI], Prostate Specific Membrane Antigen Positron Emission Tomography [PSMA-PET], Positron emission tomography [PET] choline, Computed Tomography scan [CT scan], bone scan) will be reported.

Baseline
Osteodensitometry Score
時間枠:Baseline

Osteodensitometry score, a type of imaging method used for cancer diagnostic will be reported.

Baseline
Tumor assessment: Location of Metastases
時間枠:Baseline

Location of metastases as assessed by bone and CT/MRI scans, PSMA-PET scans and any other imaging methods documented in routine practice will be recorded.

Baseline
Tumor assessment: Number of Lesions
時間枠:Baseline

Number of lesions as assessed by bone and CT/MRI scans, PSMA-PET scans and any other imaging methods documented in routine practice will be recorded.

Baseline
ECOG Performance Status
時間枠:At Baseline

ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.

At Baseline
Number of Participants with History of Treatment for Prostate Cancer
時間枠:Baseline

Participants with history of treatment for prostate cancer will be reported.

Baseline
Number of Participants Reporting Concomitant Diseases
時間枠:Baseline

Participants with Current concomitant diseases (co-morbidities) will be reported.

Baseline
Number of Participants With Vital Sign Assessments
時間枠:Baseline

Participants with relevant vital sign assessment (blood pressure and pulse) will be reported.

Baseline
Time from Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Diagnosis to Treatment Initiation
時間枠:Baseline up to 12 months

Time from mHSPC diagnosis to treatment initiation is defined as the time between date of mHSPC diagnosis and first administration of apalutamide.

Baseline up to 12 months
Percentage of Participants Reaching Undetectable PSA
時間枠:At Months 3,6,9,12

Percentage of participants with undetectable PSA levels that is PSA level less than or equal to (<=) 0.2 nanogram per milliliter (ng/mL) will be reported.

At Months 3,6,9,12
Percentage of Participants Reaching Ultralow (UL) PSA
時間枠:At Months 3,6,9,12

Percentage of participants with ultralow PSA levels that is PSA level <= 0.02 ng/mL will be reported.

At Months 3,6,9,12
Time to Undetectable PSA
時間枠:Up to 12 months

Time to undetectable PSA is defined as the time between first administration of apalutamide and date of undetectable PSA.

Up to 12 months
Time to UL PSA
時間枠:Up to 12 months

Time to UL PSA is defined as the time between first administration of apalutamide and date of UL PSA.

Up to 12 months
Number of Participants with Greater Than or Equal to (>=) 50% Decline in PSA Values (PSA 50) from Baseline
時間枠:Baseline up to 12 months

Participants with >=50% reduction in PSA value from baseline will be reported.

Baseline up to 12 months
Number of Participants with >= 90% Decline in PSA Values (PSA 90) from Baseline
時間枠:Baseline up to 12 months

Participants with >=90% reduction in PSA value from baseline will be reported.

Baseline up to 12 months
Number of Participants with Decrease in PSA Levels (PSA Halving-time)
時間枠:Up to 12 months

Participants with decrease in PSA levels (PSA halving-time) over time will be reported.

Up to 12 months
Progression-Free Survival (PFS)
時間枠:At Months 3,6,9,12

PFS is defined as the time from initiation of apalutamide until earliest record of disease progression determined by physician's assessment, or death.

At Months 3,6,9,12
Number of Deaths
時間枠:At Months 3,6,9,12

The number of deaths at months 3,6,9 and 12 will be reported.

At Months 3,6,9,12
Number of Participants Reporting Change Since Baseline in Apalutamide and ADT Modalities
時間枠:At Baseline, Months 3,6,9,12

Participants reporting changes since baseline in Apalutamide and ADT Modalities (that is, dose, route of administration, number of tablets, time of intake) will be reported.

At Baseline, Months 3,6,9,12
Time from mHSPC Diagnosis to ADT Treatment Initiation
時間枠:Baseline up to Month 12

Time from mHSPC diagnosis to ADT treatment initiation will be reported.

Baseline up to Month 12
Time Between ADT and Apalutamide Treatment Initiation
時間枠:Baseline up to Month 12

Time between ADT and apalutamide initiation will be reported.

Baseline up to Month 12
Number of Participants with Apalutamide Treatment Discontinuation
時間枠:At Months 3,6,9,12

Participants who have discontinued apalutamide treatment will be reported.

At Months 3,6,9,12
Reasons for Discontinuation of Apalutamide Treatment
時間枠:At Months 3,6,9,12

Participants who have discontinued apalutamide treatment and the reasons for discontinuation will be reported.

At Months 3,6,9,12
Time to Discontinuation of Apalutamide Treatment
時間枠:At Months 3,6,9,12

Time to discontinuation of apalutamide treatment will be reported.

At Months 3,6,9,12
Number of Participants Receiving Planned Subsequent Treatment for Prostate Cancer
時間枠:At Months 3,6,9,12

Participants receiving planned subsequent treatment for prostate cancer will be reported.

At Months 3,6,9,12
Percentage of Participants who Consulted for Treatment
時間枠:At Months 3,6,9,12

The percentage of participants who consulted for treatment will be reported.

At Months 3,6,9,12
Percentage of Participants who Used Caregiver Support
時間枠:At Months 3,6,9,12

Percentage of participants who use caregiver support will be reported.

At Months 3,6,9,12
Number of Participants Receiving Concomitant Treatments
時間枠:At Baseline, Months 3,6,9,12

Participants receiving concomitant treatments will be reported.

At Baseline, Months 3,6,9,12
Number of Participants with a Change in Concomitant Treatments
時間枠:At Months 3,6,9,12

Participants with a change in concomitant treatments will be reported.

At Months 3,6,9,12
Number of Participants Experiencing At Least One Adverse Event (AE)
時間枠:At Months 3,6,9,12

An adverse event is any untoward medical occurrence in a participant administered a medicinal product. An adverse event does not necessarily have a causal relationship with the treatment. A serious adverse event is any untoward medical occurrence that at any dose: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a suspected transmission of any infectious agent via a medicinal product or is medically important. Severity of AEs will be graded as follows: Mild (Easily tolerated symptoms), Moderate (Sufficient discomfort, causes interference with normal activity) and Severe (Extreme distress).

At Months 3,6,9,12
Percentage of Undetectable PSA According to Adherence Levels
時間枠:At Months 3,6,9,12

Percentage of undetectable PSA according to adherence levels, that is PSA level <= 0.2 ng/mL will be reported.

At Months 3,6,9,12
Percentage of UL PSA According to Adherence Levels
時間枠:At Months 3,6,9,12

Percentage of UL PSA according to adherence levels, that is PSA level <= 0.02 ng/mL will be reported.

At Months 3,6,9,12
Number of Participants with PSA 50 Response According to Adherence Levels
時間枠:At Months 3,6,9, and 12

Participants with >=50% reduction in PSA value from baseline according to adherence levels will be reported.

At Months 3,6,9, and 12
Number of Participants with PSA 90 Response According to Adherence Levels
時間枠:At Months 3,6,9, and 12

Participants with >=90% reduction in PSA value from baseline according to adherence levels will be reported.

At Months 3,6,9, and 12
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Use of Concomitant Treatments
時間枠:Up to 12 months

Participants using the concomitant treatments will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Prostate Specific Antigen (PSA) Rate
時間枠:Up to 12 months

Clinical risk factors for prostate specific antigen (PSA) rate will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Socio-professional Category
時間枠:Up to 12 months

Participants with socio-professional category will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Use of Disease Specialized Consultations
時間枠:Up to 12 months

Participants reporting the use of disease specialized consultations will be reported.

Up to 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Janssen-Cilag France Clinical Trial、Janssen-Cilag France

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月18日

一次修了 (推定)

2028年1月3日

研究の完了 (推定)

2028年9月18日

試験登録日

最初に提出

2026年1月26日

QC基準を満たした最初の提出物

2026年3月4日

最初の投稿 (実際)

2026年3月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する